Long-term treatment of anxiety disorders with pregabalin: A 1 year open-label study of safety and tolerability

Current Medical Research and Opinion

Volumn 29, Issue 10, 2013, Pages 1223-1230

  Montgomery, Stuart ^a   Emir, Birol ^b   Haswell, Hannah ^c   Prieto, Rita ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b PFIZER INC   (United States)

^c Pfizer Ltd Surrey   (United Kingdom)

Author keywords

Anti anxiety agents; Anxiety disorder; Anxiolytic agents; Pregabalin

Indexed keywords

ALPRAZOLAM; PLACEBO; PREGABALIN; VENLAFAXINE;

ACCIDENTAL INJURY; ADULT; AGED; ANXIETY DISORDER; ARTICLE; ASTHENIA; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HUMAN; INCIDENCE; INFECTION; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PANIC; PHARYNGITIS; SHORT COURSE THERAPY; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANXIETY DISORDERS; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84884482272     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.820694     Document Type: Article

References (35)

1. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe-a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005;15:357-76 (Pubitemid 40943541)
2. Kessler RC, Wang PS. The descriptive epidemiology of commonly occurring mental disorders in the United States. Annu Rev Public Health 2008;29:115-29 (Pubitemid 351600402)
3. Keller MB. The long-term clinical course of generalized anxiety disorder. J Clin Psychiatry 2002;63(Suppl 8):11-16 (Pubitemid 34535252)
4. Bruce SE, Yonkers KA, Otto MW, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 2005;162:1179-87 (Pubitemid 40770702)
5. Angst J, Gamma A, Baldwin DS, et al. The generalized anxiety spectrum: prevalence, onset, course and outcome. Eur Arch Psychiatry Clin Neurosci 2009;259:37-45
6. Rodriguez BF, Weisberg RB, Pagano ME, et al. Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. J Nerv Ment Dis 2006;194:91-7 (Pubitemid 43260187)
7. Feltner D, Wittchen HU, Kavoussi R, et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008;23:18-28 (Pubitemid 350294866)
8. Montgomery SA, Sheehan DV, Meoni P, et al. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res 2002;36:209-17 (Pubitemid 34626371)
9. Stocchi F, Nordera G, Jokinen RH, et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 2003;64:250-8 (Pubitemid 36457322)
10. Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2006;9:495-505 (Pubitemid 44607202)
11. Davidson JR, Wittchen HU, Llorca PM, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2008;18:673-81
12. Baldwin DS, Loft H, Florea I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharmacol 2012;27:197-207
13. Katzman MA, Brawman-Mintzer O, Reyes EB, et al. Extended release quetia-pine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol 2011;26:11-24
14. Mavissakalian MR, Perel JM. Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 1999;56:821-7 (Pubitemid 29420703)
15. Walker JR, Van Ameringen MA, Swinson R, et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 2000;20:636-44
16. Rapaport MH, Wolkow R, Rubin A, et al. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 2001;104:289-98 (Pubitemid 32906975)
17. Kamijima K, Kuboki T, Kumano H, et al. A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan. Int Clin Psychopharmacol 2005;20:265-73 (Pubitemid 41192147)
18. Montgomery SA, Tobias K, Zornberg GL, et al. Efficacy and safety of prega-balin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006;67:771-82 (Pubitemid 43946184)
19. Ferguson JM, Khan A, Mangano R, et al. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J Clin Psychiatry 2007;68:58-68 (Pubitemid 46220125)
20. Greist JH, Liu-Dumaw M, Schweizer E, Feltner D. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. Int Clin Psychopharmacol 2011;26:243-51
21. Mico JA, Prieto R. Elucidating the mechanism of action of pregabalin: alpha(2)delta as a therapeutic target in anxiety. CNS Drugs 2012;26:637-48
22. Montgomery SA, Kasper S. Pharmacotherapy update: pregabalin in the treatment of generalized anxiety disorder. Clin Med Insights Ther 2010;2:189-202
23. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003;160:533-40 (Pubitemid 41094262)
24. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003;23:240-9 (Pubitemid 36807791)
25. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005;25:151-8 (Pubitemid 40395093)
26. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005;62:1022-30 (Pubitemid 41248382)
27. Montgomery S, Chatamra K, Pauer L, et al. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry 2008;193:389-94
28. Kasper S, Herman B, Nivoli G, et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009;24:87-96
29. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004;24:141-9 (Pubitemid 38380837)
30. Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol 2011;26:213-20
31. Pfizer. A 10-Week, Randomized, Double-Blind, Placebo-Controlled Study of Paroxetine and Pregabalin in Patients With Social Phobia. Protocol 1008-081 (2002). (data on file)
32. Pfizer. A 10-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Pregabalin and Paroxetine in the Treatment of Panic Disorder. Protocol 1008-091 (2002). (data on file)
33. Guy W. ECDEU Assessment Manual for Psychopharmacology. DHEW publication no (ADM) 76-338. Rockville, MD: U.S. Dept of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Programs, 1976
34. Cabrera J, Emir B, Dills D, et al. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin 2012;28:1027-37
35. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001;179:15-22